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Background: Plasmid-based overexpression of genes has been the principal strategy for metabolic engineering.
However, for biotechnological applications, plasmid-based expression systems are not suitable because of genetic
instability, and the requirement for constant selective pressure to ensure plasmid maintenance.
Results: To overcome these drawbacks, we constructed an Escherichia coli lycopene production strain that does not
carry a plasmid or an antibiotic marker. This was achieved using triclosan-induced chromosomal evolution, a high
gene copy expression system. The engineered strain demonstrated high genetic stability in the absence of the
selective agent during fermentation. The replacement of native appY promoter with a T5 promoter, and the
deletion of the iclR gene in E. coli CBW 12241 further improved lycopene production. The resulting strain, E. coli
CBW 12241(ΔiclR, PT5-appY), produced lycopene at 33.43 mg per gram of dry cell weight.
Conclusions: A lycopene hyper-producer E. coli strain that does not carry a plasmid or antibiotic marker was
constructed using triclosan-induced chromosomal evolution. The methods detailed in this study can be used to
engineer E. coli to produce other metabolites.
Keywords: Lycopene, Escherichia coli, Chemically induced chromosomal evolution, Metabolic engineeringBackground
Carotenoids are a diverse class of C40 isoprenoids that
have multiple physiological and nutritional functions in
many organisms. Carotenoids have received considerable
attention from the food industry, medicine and cos-
metics because of their interesting pigment properties,
and more importantly, their potential beneficial effects on
human health. Lycopene is an effective antioxidant [1] and
has beneficial biological and pharmaceutical activities,
including anti-cancer [2], anti-inflammatory [3], and anti-
oxidative activities [4]. Lycopene is widely used as a sup-
plement in functional foods, animal feed, nutraceuticals,
pharmaceuticals and as an additive in cosmetics.
Potential commercial applications mean that efficient
biotechnological production of lycopene has become in-
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reproduction in any medium, provided the ordescribed its production using metabolic engineering
[5-21]. However, all of these above studies focused on
the deletion of undesirable genes and plasmid overex-
pression of key genes. Such plasmid-based expression
systems have several drawbacks, including structural in-
stability, segregational instability or allele segregation
[22-24]. These plasmid instabilities cause genetic in-
stability, which reduces the production of the compound
of interest. Tyo et al. reported that plasmid-carrying
strains lost poly-3-hydroxybutyrate (PHB) productivity
after 40 generations with antibiotics [25]. Moreover,
antibiotic resistance genes are the most commonly used
markers for selecting and maintaining plasmids in hosts
during cultivation. However, antibiotics are both costly
and banned from food and pharmaceutical production
processes. There is also a potential risk of the spread of
antibiotic-resistant marker to other microbes in nature,
leading to the rapid emergence of multidrug-resistant
organisms (e.g., superbacteria) [26,27].
These drawbacks of using plasmids can be overcome
by integration of genes into the chromosome. Recently,
Tyo et al. developed a plasmid-free method for the over-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Lycopene production of CIChE strains at different
triclosan concentrations cultured in 2YT medium supplemented
with 5 g/L KAc.
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numbers of the desired genes, termed chemically induced
chromosomal evolution (CIChE) [25]. Genes of interest
were inserted into chromosome of Escherichia coli by the
λInCh genomic integration method, and then evolved to
the desired gene copy number by chemical induction.
However, the λInCh genomic integration protocol is com-
plicated and time-consuming, because it contains three
steps that involve two recombination steps. Chiang et al.
modified the conditional-replication, integration, and
modular plasmid system produced by Haldimann and
Wanner [28], and developed a replicon-free and marker-
less method (RMM) for the chromosomal insertion of
genes [26]. Genes of interest can be directly integrated
into the bacterial attachment site of the E. coli chromo-
some as single copies, through transformation. However,
the CIChE strains reported by Tyo et al. still have an anti-
biotic resistance marker (chloramphenicol resistance) [25].
To avoid the use of antibiotic resistance genes and anti-
biotics, Goh and Good developed a novel system using
the widely used the biocide triclosan as the selective agent
and the essential growth gene fabI of E. coli as the select-
ive marker [27]. Thus, to overcome the drawbacks of
CIChE as originally developed by Tyo et al., we developed
a series of integration expression vectors, pXKF3T5b, for
triclosan induction chromosomal evolution in our previ-
ous paper [29]. Using these vectors, genes of interest can
be inserted into E. coli site-specifically by transformation
using RMM. The gene copy number can then be evolved
to the desired value by triclosan induction. In this study,
we constructed a lycopene hyper-producer E. coli that
does not carry plasmid or antibiotic marker, using the
CIChE integration expression vector. To the best of our
knowledge, this is the first report of metabolic engineering
of an E. coli that does not carry a plasmid or antibiotic
marker using a multiple gene expression system for
lycopene production.
Results and discussion
CIChE of E. coli for lycopene production
To overcome the drawbacks of CIChE as originally
devised by Tyo et al., we developed a series of integration
expression vectors, pXKF3T5b, for triclosan induction
chromosomal evolution in our previous paper [29]. Using
these vectors, genes of interest can be inserted into E. coli
site-specifically by transformation using RMM. The gene
copy number can then be evolved to the desired value by
triclosan induction. Thus, strains constructed using our
CIChE integration expression vectors have no antibiotic
resistance and are environmentally safe.
The CIChE integration expression vector containing the
lycopene biosynthetic gene cluster (pP21KF3T5b-EIBipi)
was transferred into E. coli BW25113 (ΔgdhAΔaceE,
PT5-dxs) and then increasing triclosan concentration wasused to induce CIChE. Figure 1 shows the results of lyco-
pene production in CIChE strains resistant to different tri-
closan concentrations. Lycopene production in CIChE
strains increases with increasing triclosan concentration
during chromosomal evolution. The maximum lycopene
production of 9.55 ± 0.23 mg/g dry cell weight (DCW)
was obtained by the CIChE strains resistant to 8 μM tri-
closan cultured in 2YT medium. Figure 2 shows that the
crtI gene copy number of the CIChE strains increases with
triclosan concentration during chromosomal evolution. At
a triclosan concentration of 8 μM, the copy number
reached about 30 in the CIChE strains, which is the
equivalent copy number of a medium to high copy plas-
mid. When the triclosan concentration was above 8 μM,
the gene copy number still increased; however, the lyco-
pene production of the CIChE strains did not increase.
The results indicated that there is an optimal copy
number of the crt genes for efficient production of
lycopene. Thus, the recA gene of the CIChE strain that
was resistant to 8 μM triclosan was deleted to obtain
E. coli CBW12241, in which homologous recombination,
which could reduce the copy number, is inhibited. The crt
gene number of the recA-deleted strain did not change
(data not shown). The genetic stability was also assayed
(Table 1). The level of lycopene production in E. coli
CBW12241 remained constant after 30 rounds of subcul-
turing without triclosan. However, the plasmid-bearing
strain E. coli BW25113 (ΔgdhAΔaceE, PT5-dxs, pBAD24-
WZM1) lost lycopene productivity sharply, whether cul-
tured with antibiotics or not. With antibiotics, the level of
lycopene production in the plasmid-bearing strain, E. coli
BW25113 (ΔgdhAΔaceE, PT5-dxs, pBAD24-WZM1), was
only about 30% of that of the parent strain after 30 rounds
of subculturing. Without antibiotics, the lycopene prod-
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Figure 2 Copy number of the crtI gene in CIChE strains at
different triclosan concentrations.
Table 2 Effect of plasmid-based overexpression of genes
on lycopene production in the CIChE strain E. coli
CBW12241*
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after 30 rounds of subculturing. These results are consist-
ent with previous reports wherein the gene copy number
and PHB production of a CIChE strain remained constant
after 40 rounds of subculturing [25]. They also found that
PHB productivity of the plasmid-carrying strain cultured
with antibiotics was completely lost after 40 generations.
The loss of productivity in the plasmid system with anti-
biotics may be due to allele segregation. It is likely to
occur regularly, despite antibiotic selection, particularly in
subculturing experiments or in chemostats [25].
Optimization of the lycopene synthetic pathway
Overexpression of the idi, dxs, pck, pps, rpoS, appY, yjiD,
ycgW, wrbA and atpE genes are reported to improve
lycopene production in E. coli [8-19,21]. Thus, theTable 1 Genetic stability of the CIChE and the plasmid-
carrying straina
Number of subculture OD600 Specific lycopene
content (mg/gDCW)
E. coli CBW12241
1 6.85 ± 1.83 28.57 ± 0.50
5 5.59 ± 0.31 29.76 ± 0.76
10 4.37 ± 0.49 31.05 ± 1.11
15 4.47 ± 0.37 30.37 ± 1.21
20 4.61 ± 0.45 30.95 ± 1.21
25 4.39 ± 0.39 28.95 ± 0.85
30 4.92 ± 0.10 30.53 ± 1.53
E. coli BW25113 (ΔgdhAΔaceE, PT5-dxs, pBAD24-WZM1)
1 4.29 ± 0.51 7.51 ± 0.76
30, with Amp 7.15 ± 0.38 2.24 ± 0.46
30, without Amp 8.51 ± 0.45 0
a Cells were cultured in SBMSN medium supplemented with 5 g/L KAc without
triclosan at 37°C for 48 h. Data represent means of triplicate cultures ±
standard deviation.effects of over-expression of these genes in E. coli
CBW12241 on lycopene production were investigated.
The results are presented in Table 2. Surprisingly, only the
over-expression of appY slightly enhanced the specific
lycopene content. This may reflect the different genetic
backgrounds of the strains. In E. coli CBW12241, isopen-
tenyl diphosphate isomerase is overexpressed by chromo-
somal evolution of ipiHPI. Thus, overexpression of the idi
gene in E. coli CBW12241 was not beneficial to lycopene
production. Zhao et al. [30] reported that the dxs gene
from Bacillus subtilis functioned more efficiently to
enhance isoprene production in E. coli than the native dxs
gene. However, overexpression of the dxs gene from
Bacillus subtilis significantly inhibited lycopene produc-
tion in E. coli CBW12241, possibly because the T5 pro-
moter has replaced the native promoter of the dxs gene in
E. coli CBW12241.
To reduce the metabolic burden caused by the plas-
mid, the native promoter of the appY gene was replaced
with the T5 promoter to obtain E. coli CBW12241
(PT5-appY). As shown in Table 3, the replacement
improved cell growth and lycopene concentration.
Kang et al. used a shotgun approach and found that
overexpression of the appY gene improved lycopene
production [12]. The appY gene encodes a transcrip-
tional activator of two regulator energy metabolism
operons, hya and cbdAB-appA, which are induced by
anaerobiosis. They reasoned that the appY gene might
help rescue the strain from energy insufficiency caused





pBAD24 9.54 ± 0.73 57.79 ± 1.60 19.01 ± 1.64
pBappY 8.95 ± 0.08 57.75 ± 0.49 20.16 ± 0.18
pBidi 10.20 ± 0.22 62.49 ± 1.43 19.15 ± 0.66
pBpck 10.28 ± 0.46 58.87 ± 2.34 17.90 ± 0.15
pBpps 10.51 ± 0.57 60.11 ± 0.97 17.91 ± 1.29
pBrpoS 10.91 ± 0.34 60.17 ± 1.54 17.25 ± 0.99
pBycgW 10.53 ± 0.42 60.43 ± 0.92 17.96 ± 0.54
pByjiD 10.54 ± 0.10 58.29 ± 0.34 17.28 ± 0.07
pBdxs 10.25 ± 0.45 62.02 ± 1.66 18.91 ± 0.47
pQE30 7.72 ± 0.13 52.92 ± 1.53 21.42 ± 0.67
pQwrbA 13.76 ± 0.47 7.51 ± 0.58 1.71 ± 0.13
pQydeO 13.19 ± 0.17 9.81 ± 0.62 2.33 ± 0.15
pQatpE 9.73 ± 0.17 45.21 ± 0.67 14.53 ± 0.06
pQdxs 11.49 ± 0.31 25.62 ± 1.84 6.97 ± 0.64
a Cells were cultured in SBMSN medium supplemented with 5 g/L KAc without
triclosan at 37°C for 48 h. Data represent means of triplicate cultures ±
standard deviation.








E. coli CBW12241 5.87 ± 0.67 54.15 ± 3.44 28.97 ± 0.67
E. coli CBW12241
(PT5-appY)
8.56 ± 1.50 79.17 ± 7.20 29.59 ± 0.81
E. coli CBW12241
(△iclR)
5.38 ± 0.16 51.32 ± 2.86. 29.82 ± 0.78
E. coli CBW12241
(△iclR, PT5-appY)
7.49 ± 1.58 77.85 ± 1.42 33.43 ± 0.81
E. coli CBW12251 6.90 ± 1.01 70.07 ± 1.44 31.73 ± 0.48
a Cells were cultured in SBMSN medium supplemented with 5 g/L KAc without
triclosan at 37°C for 48 h. Data represent means of triplicate cultures ±
standard deviation.
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demonstrated that the deletion of the transcriptional re-
pressor iclR of the glyoxylate pathway increased lycopene
production [31]. Thus, we deleted the iclR gene and exam-
ined lycopene production. The deletion of the iclR gene in
E. coli CBW12241 caused a slight inhibition of growth
and did not affect the specific lycopene content. The dele-
tion of the iclR gene in the promoter replacement strain,
E. coli CBW12241 (PT5-appY), slightly improved specific
lycopene content, from 28.97 ± 0.67 mg/g DCW to 33.43 ±
0.81 mg/gDCW, and improved the lycopene concentration
from 54.15 ± 3.44 mg/L to 77.85 ± 1.42 mg/L (Table 3). In
the iclR gene knockout strain, the glyoxylate pathway is
constitutively active [32]. Furthermore, there are other
examples of metabolic engineering involving deleting iclR
to increase productions of compounds. Sanchez et al. suc-
cessfully knocked out iclR to boost the glyoxylate pathway
flux for succinate overproduction [33]. Lee et al. observed
aceBA upregulation in the threonine-overproducing E. coli,
and when iclR deleted, a 30% higher threonine production
was recorded [34].
Many reports have been published about lycopene pro-
duction using recombinant E. coli [5-21]. However, these
strains contain plasmids, which can cause genetic instabil-
ity and can have a negative environmental impact. Chiang
et al. [26] constructed a lycopene hyper-producer E. coli
strain that did not carry the replicon or a selective marker
using RMM. However, RMM is a single gene copy expres-
sion system. Tyo et al. [25] constructed a lycopene produ-
cer E. coli using CIChE, a plasmid-free, high gene copy
expression system. However, this strain still contained a
chloramphenicol resistance marker. In the present study,
we engineered a lycopene producer E. coli that does not
carry a plasmid or an antibiotic marker. The CIChE strain
only contains the fab I gene, which is essential for the
growth of E. coli. The strain does not present the safety
problems associated with antibiotic resistance genes in
plasmids. Moreover, the strain does not require thepresence of the resistance compound (triclosan) during
the fermentation process. To the best of our knowledge,
this is the first report of engineering an E. coli that does
not carry a plasmid or antibiotic marker using a high gene
copy expression system.
The maximum specific lycopene content (33.43 mg/g
DCW) of E. coli CBW12241 (ΔiclR, PT5-appY) was higher
than that of the CIChE strain reported by Tyo et al. (about
11 mg/gDCW) [25]. The value was also higher than other
plasmid-carrying strains, which achieved 22 mg/g DCW
[21], 18 mg/g DCW [6] or 32 mg/g DCW produced by
the engineered E. coli containing heterologous lycopene
and mevalonate pathways [35]. However, the yield is
slightly lower than that reported by Chiang et al.
(38.5 mg/g DCW) [26]. In their study, the RMM strain E.
coli BL21-CrtD1K has an additional chromosomal copy of
dxs fused to the T7 promoter. However, plasmid-based
overexpression of the dxs gene in the CIChE strain did
not further enhance lycopene production. Moreover, E.
coli CBW12251, containing an additional chromosomal
copy of the dxs gene, produced lycopene at 31.73 ±
0.48 mg/gDCW, which was lower than E. coli CBW12241
(ΔiclR, PT5-appY) (Table 3).
Although the yield of our engineered E. coli harbor-
ing only a heterologous lycopene pathway achieved the
advanced levels quoted in the literature, many papers
have reported that the introduction of a heterologous
mevalonate pathway improved production of isoprenoids
such as lycopene [16,17,20,35], CoQ10 [36], α-farnesene
[37], terpenoid [38], taxol [39] and amorphadiene [40].
Thus, integration of a heterologous mevalonate path-
way into the chromosome of the engineered E. coli
CBW12241 (ΔiclR, PT5-appY) may further improve
lycopene production.
Conclusions
We constructed a lycopene producer E. coli strain that
does not carry a plasmid or antibiotic marker using
CIChE, replacement of a promoter as well as knockout
of a gene. No resistance compound was required during
the fermentation process using this strain. This is the
first report of engineering an E. coli that lacks a plasmid
and an antibiotic marker using a high gene copy expres-
sion system. The engineered strain remained stable, as
determined by its lycopene production, after 30 sequen-
tial transfers.
Methods
Strains, primers and plasmids
The strains and plasmids used in this study are listed in
Table 4. E. coli DH5α was used for plasmid construction.
E. coli BW2511 (ΔaceFΔgdhA, PT5-dxs) [19] was used as
the parent strain for chromosomal integration. The pri-
mers used in this study are listed in Table 5.
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The crtE, crtI, crtB and ipi gene cluster was cut from
pBAD24-WZM1 [19] using restriction enzymes ClaI and
HindIII and treated with Primestar HS DNA polymerase
(TaKaRa, China) and digested with EcoRI. The resulting
gene cluster was cloned into the EcoRI/BamHI sites of
pP21KF3T5b [29] to obtain pP21KF3T5b-crtEIBipi. The
resulting integration vector was inserted into the bacterialTable 4 List of bacterial strains and plasmids used in this stud
Strain or plasmid Descriptiona
Strains
E. coli DH5α supE44 Δ(lacZYA-argF) U169 (Φ80lacZ ΔM15) h
E. coli BW25113 lacIq rrnBT14 ΔlacZWJ16 hsdR514 ΔaraBADAH33 Δ
E. coli BW25113
(ΔgdhAΔaceE, PT5-dxs)
E. coli BW25113, ΔgdhA, ΔaceE, replacement o
E. coli CBW12241 CIChE strain of E. coli BW25113 (ΔgdhAΔaceE,
E. coli CBW12241 (PT5-appY) E. coli CBW12241, replacement of native prom
E. coli CBW12241 (ΔiclR) E. coli CBW12241, ΔiclR
E. coli CBW12241 (ΔiclR, PT5-
appY)
E. coli CBW12241(PT5-appY), ΔiclR
E. coli CBW12251 E. coli CBW12241 (ΔiclR, PT5-appY) with an add
T5 promoter
Plasmid
pP21KF3T5b CIChE integration expression vector, Kanr
pP21KF3T5b-crtEBIipi pP21KF3T5b derivative containing crtE, crtB an
Haematococcus pluvialis, Kanr
pAH121 Helper plasmid expressing phage P21 Int, Am
pBAD24-WZM1 pBAD24 derivative containing crtE, crtB and cr
Haematococcus pluvialis, Ampr
pSIM6 pSC101 repliconts PL-gam-bet-exo cI857, Amp
r
pKD4 oriRγ, FRT::kan::FRT template plasmid, Kanr, Am
pCP20 pSC101 repliconts Flp(λRp) cI857, Cmr, Ampr
pBAD24 pMB1 ori, PBAD L-arabinose inducible, Amp
r
pBappY pBAD24 derivative containing the appY gene
pBidi pBAD24 derivative containing the idi gene fro
pBpck pBAD24 derivative containing the pck gene fr
pBpps pBAD24 derivative containing the pps gene fr
pBrpoS pBAD24 derivative containing the rpoS gene f
pBycgW pBAD24 derivative containing the ycgW gene
pByjiD pBAD24 derivative containing the yjiD gene fr
pQE30 ColE1 ori, PT5 IPTG inducible, Amp
r
pQEwrbA pQE30 derivative containing the wrbA gene fr
pQydeO pQE30 derivative containing the ydeO gene fr
pQatpE pQE30 derivative containing the atpE gene fro
pQdxs pQE30 derivative containing the dxs gene from
aAmpr: ampicillin resistance; Cmr: chloramphenicol resistance; Kanr: kanamycin resis
phytoene desaturase; ipiHPI: isopentenyl diphosphate isomerase from Haematococc
diphosphate isomerase; pck: phosphoenolpyruvate carboxykinase; pps: phosphoeno
proteolysis; yjiD: inhibitor of σS proteolysis; wrbA: NAD(P)H: quinone oxidoreductase
complex, c subunit; dxs: 1-deoxy-D-xylulose-5-phosphate synthase.attachment (attB) site of E. coli using a helper plasmid,
pAH121, expressing the phage integrase, by direct trans-
formation, as described by Chiang et al. [26]. The general
procedure for using the integration vector is illustrated in
Figure 3. In brief, strains containing the helper plasmid
pAH121 were first cultured in super optimal broth (SOB)
medium with 100 μg/mL of ampicillin (Amp) at 30°C to
an optical density at 600 nm of approximately 0.6. They
Source or
reference
sdR17 recA endA1 gyrA96 thi-1 relA1 Invitrogen
rhaBADLD78 42
f native promoter of the dxs gene with T5 promoter 19
PT5-dxs) resistance to 8 μM triclosan, ΔrecA This study
oter of the appY gene with T5 promoter This study
This study
This study
itional chromosomal copy of dxs under the control of
29
d crtI gene from Pantoea agglomerans and ipiHPI from This study
pr 28





from E. coli, Ampr This study
m E. coli, Ampr This study
om E. coli, Ampr This study
om E. coli, Ampr This study
rom E. coli, Ampr This study
from E. coli, Ampr This study
om E. coli, Ampr This study
Qiagen
om E. coli, Ampr This study
om E. coli, Ampr This study
m E. coli, Ampr This study
Bacillus subtilis, Ampr This study
tance; crtE: geranylgeranyl diphosphate synthase; crtB: phytoene synthase; crtI:
us pluvialis; appY: DNA-binding transcriptional activator; idi: isopentenyl
lpyruvate synthetase; rpoS: RNA polymerase sigma 38; ycgW: inhibitor of σS
; ydeO: DNA-binding transcriptional dual regulator; atpE: ATP synthase, F0
Table 5 Primers used in this study
Primers Sequence and purposea
BLP1 50- ATCGCCTGTATGAACCTG -30, Diagnostic PCR in attPP21
integration
BLP4 50- TAGAACTACCACCTGACC -30, Diagnostic PCR in attPP21
integration
AHP2 50- ACACTTAACGGCTGACATGG -30, Diagnostic PCR in attPP21
integration
AHP3 50- AACGAGTATCGAGATGGCAC -30, Diagnostic PCR in attPP21
integration
CGA 50- TCAAGAATCTGGTGACCGAGGAG -30, Diagnostic PCR in
attPP21 integration
CGB 50- ACGCCGCTTCAATGACGCTG -30, Diagnostic PCR in attPP21
integration
VCA1 GTCGTCAGGCTACTGCGTATG. Diagnostic PCR in recA deletion
VCA2 CACGATCCAACAGGCGAG. Diagnostic PCR in recA deletion
NDF 50- TGGTAATAATGGCTTCGTCTG -30, qPCR for the minD gene
NDR 50- GCGATAAAGATGCCCTCAC -30, qPCR for the minD gene
QCF 50- CCAGGAGGGATATTTGC -30, qPCR for the crtI gene
QCR 50- CAGGGAGTGGAACGAGAAG -30, qPCR for the crtI gene
wrbAR 50- CGGTCGACGCGTATCCTCCTGTTGAAGATTAG CCGTT -30
yedeOF 50- GCGTCGACAGGAGAGATAAAATGTCGCTCGT TTGTTCT -30
ydeOR 50- GGTCTCTGCAGTCAAATAGCTAAAGCATTCATCGT -30
atpEF 50- GAGAGCTCAGGAGGACTGTCATGGAAAACCTGAAT -30
atpER 50- CGGGGTACCTAAATAAAAGCAACGCTTACTACGC -30
dxsF 50-CTGGGATCCAGGAGATCCGCTATGGATCTTTTATCAA
TACAGGAC-30
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the integration vector pP21KF3T5b-crtEIBipi. Following
electroporation, the cells were suspended in SOB plus glu-
cose medium without Ampicillin, incubated at 37°C for
1 h and at 42°C for 30 min, and then spread onto
Luria-Bertani (LB) agar plates containing 25 μg/mL of
kanamycin (Kan) and incubated overnight at 37°C.
Colonies were verified by colony PCR using primer sets
BLP1 and CGA, or BLP4 and CGB (Table 5). Positive col-
onies were cultured in 5 mL LB medium with 25 μg/mL
kanamycin at 42°C overnight and then spread onto an LB
medium with Kan agar plate at 37°C overnight. Stable
integration was scored by antibiotic resistance (conferring
Kan resistance) and loss of the helper plasmid (conferring
Amp sensitivity), as well as by colony PCR using primer
sets BLP1 and CGA, or BLP4 and CGB (Table 5). To elim-
inate the region containing the selective marker (Kan
resistance) and the replication origin, the resulting inte-
grants bearing the inserted DNA were transformed with
pCP20 expressing FLP recombinase [23]. Colonies only
resistant to triclosan were verified by colony PCR using
primer sets BLP1 and CGA, or BLP4 and CGB.
CIChE of the above construct was carried out by sub-
culturing the resulting strains in 5 mL SOB medium
with increasing concentrations of triclosan, in 15 mL
culture tubes, as described by Tyo et al. [25]. The strains
were grown to stationary phase in 1 μM triclosan. Fifty
milliliters of the culture was subcultured into a new cul-
ture tube. In the new tube, the triclosan concentration
was doubled from 2 μM to 64 μM and allowed to grow
to stationary phase. The process was repeated until the
desired concentration was reached. The recA gene of the










APFP 50- CTCCGTATAGAGTTCCATCGT -30, Diagnostic PCR in theConstruction of the plasmid
The appY, idi, pck, pps, rpoS, ycgW and yjiD genes were
amplified from E. coli genomic DNA using the primers
shown in Table 5, and ligated into pBAD24 [41], respect-
ively. The wrbA, ydeO and atpE genes were amplified
from genomic DNA of E. coli using the primers shown
in Table 5 and ligated into pQE30, respectively. The dxs
gene was amplified from genomic DNA of B. subtilis
ATCC 6633 using primers dxsF and dxsR (Table 5) and
ligated into pQE30 (Qiagen).replacement of appY promoter
APRP 50- GCCACATTTCTGGGCTACGAC -30, Diagnostic PCR in the
replacement of appY promoter
IKFP 50- TGTTTATCAAGAGTGTCTGAGCGT -30, Diagnostic PCR in the
deletion of the iclR gene
IKRP 50- CGTTTTCACCGCAAATACCG -30, Diagnostic PCR in the
deletion of the iclR gene
a Restriction enzyme sites are underlined.Knockout of genes
Gene knockouts and replacement of the native promoter
of the appY gene with the T5 promoter were carried out
by PCR product recombination [42] using the pSIM6
plasmid [43] expressing the lambda red recombination
system and pKD4 [42] as the template for PCR. Gene
knockouts were verified using colony PCR using the ap-
propriate primers (Table 5).
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http://www.biomedcentral.com/1472-6750/13/6Quantitative PCR (qPCR) measurement of gene copy
number
Gene copy numbers were measured by qPCR on gen-
omic DNA isolated from the appropriate CIChE strains.
qPCR was performed with an iCycler iQ5 Real Time
PCR system (Bio-Rad Laboratories, USA) using the
SYBR Premix Ex Taq II (TaKaRa, China), following the
manufacturer’s protocol. PCR conditions were as follows:
30 s at 95°C; 40 cycles of at 95°C for 5 s, 60°C for 30 s,
and 95°C for 60 s; followed by melting curve analysis.
The copy numbers of the crtI gene were detected and
compared to the copy number of minD, a nearby native
gene in the chromosome. The primers QCF and QCR
(Table 5) were used to measure the copy number of crtI.
The primers NDF and NDR (Table 5) were used to
measure the copy number of minD.
Lycopene production
For lycopene production, 5 mL of LB medium supple-
ment with 5 g/L KAc was used for overnight precultiva-
tion of E. coli in a falcon tube at 37°C. The mainFigure 3 Change in genomic structure induced by integration of pP2
(Table 5) were used to verify the genomic structure by colony PCR. The nu
amplified using corresponding primer sets (shown by arrows).cultures were in 2YT medium or SBMSN medium sup-
plemented with 5 g/L KAc. SBMSN medium (pH7.0)
contains (g/L): peptone 12, yeast extract 24, KH2PO4
1.7, K2HPO4 11.42, MgCl2·6H2O 1, ammonium oxalate
1.42, Tween-80 2. The main cultures were inoculated
with a starting OD600 of 0.1 and incubated at 37°C for
24 h in a rotary shaking incubator at 150 rpm. Cell
growth was measured by optical density at 600 nm and
converted into DCW (g/L) using a standard curve.
Extraction and measurement of lycopene
The lycopene content of recombinant E. coli strains was
quantified as previously reported [5]. Two hundred fifty
microliters of E. coli cells were harvested by centrifuga-
tion at 12000 rpm for 5 min. The cell pellet was washed
with water and then extracted in 1 mL of acetone at 55°C
for 15 min with intermittent vortexing. The mixture
was then centrifuged at 12000 rpm for 10 min, and the
acetone supernatant was transferred to a new tube.
The absorbance of the resulting extract was measured
at 474 nm and converted to lycopene concentration1KF3T5b-crtEIBipi at the attPP21 site. Primers BLP1, BLP4, CGA, CGB
mbers beside the bars represent the expected sizes of PCR fragments
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mercial lycopene (Sigma).Statistical analysis
All experiments were conducted in triplicate, and data
were averaged and presented as the mean ± standard devi-
ation. One-way analysis of variance followed by Tukey’s
test was used to determine significant differences using
the OriginPro (version 7.5) package. Statistical significance
was defined as p < 0.05.
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